Ordering Recommendation

Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy for CSF specimens only.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation


Specimen Preparation

Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min: 0.75 mL)

Storage/Transport Temperature


Unacceptable Conditions

Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.


Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)


Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot


Sun, Wed, Fri


1-6 days

Reference Interval

Test Number
Reference Interval
  Paraneoplastic Abs (PCCA/ANNA) IgG, CSF None Detected

Interpretive Data

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)


PCCA/ANNA antibodies are screened by IFA. If the IFA screen is indeterminate then the Immunoblot will be added. If the IFA screen is positive at 1:1, then a specific titer (PCCA or ANNA) and Immunoblot will be added. Additional charges apply.

Hotline History


CPT Codes

86255; if reflexed add 84182 x4 and/or 86256


Component Test Code* Component Chart Name LOINC
2010842 Paraneoplastic Abs (PCCA/ANNA) IgG, CSF 14247-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot, CSF